These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 32334266)
1. Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors. Matheson CJ; Casalvieri KA; Backos DS; Minhajuddin M; Jordan CT; Reigan P Eur J Med Chem; 2020 Jul; 197():112316. PubMed ID: 32334266 [TBL] [Abstract][Full Text] [Related]
2. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity. Mahmoud HK; Farghaly TA; Abdulwahab HG; Al-Qurashi NT; Shaaban MR Eur J Med Chem; 2020 Dec; 208():112752. PubMed ID: 32947227 [TBL] [Abstract][Full Text] [Related]
3. Activating Effect of 3-Benzylidene Oxindoles on AMPK: From Computer Simulation to High-Content Screening. Novikova DS; Grigoreva TA; Ivanov GS; Melino G; Barlev NA; Tribulovich VG ChemMedChem; 2020 Dec; 15(24):2521-2529. PubMed ID: 32762073 [TBL] [Abstract][Full Text] [Related]
4. Pharmacophore based drug design and synthesis of oxindole bearing hybrid as anticancer agents. Pathak A; Pandey V; Raj Pokharel Y; Devaraji V; Ali A; Haider K; Saad S; Dewangan RP; Siddiqui N; Shahar Yar M Bioorg Chem; 2021 Nov; 116():105358. PubMed ID: 34544029 [TBL] [Abstract][Full Text] [Related]
5. Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation. Bort A; Quesada S; Ramos-Torres Á; Gargantilla M; Priego EM; Raynal S; Lepifre F; Gasalla JM; Rodriguez-Henche N; Castro A; Díaz-Laviada I Sci Rep; 2018 Mar; 8(1):4370. PubMed ID: 29531259 [TBL] [Abstract][Full Text] [Related]
6. Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile. Sestito S; Bacci A; Chiarugi S; Runfola M; Gado F; Margheritis E; Gul S; Riveiro ME; Vazquez R; Huguet S; Manera C; Rezai K; Garau G; Rapposelli S Eur J Med Chem; 2021 Dec; 226():113895. PubMed ID: 34624821 [TBL] [Abstract][Full Text] [Related]
7. Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances. Dhokne P; Sakla AP; Shankaraiah N Eur J Med Chem; 2021 Apr; 216():113334. PubMed ID: 33721669 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and molecular docking of new sulfonamide-based indolinone derivatives as multitargeted kinase inhibitors against leukemia. El-Hussieny M; El-Sayed NF; Fouad MA; Ewies EF Bioorg Chem; 2021 Dec; 117():105421. PubMed ID: 34666258 [TBL] [Abstract][Full Text] [Related]
9. Targeting tyrosine kinase: Development of acridone - pyrrole - oxindole hybrids against human breast cancer. Kaur M; Singh P Bioorg Med Chem Lett; 2019 Jan; 29(1):32-35. PubMed ID: 30446310 [TBL] [Abstract][Full Text] [Related]
10. Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer. Kuramoto K; Yamada H; Shin T; Sawada Y; Azami H; Yamada T; Nagashima T; Ohnuki K Bioorg Med Chem; 2020 Mar; 28(5):115307. PubMed ID: 32007387 [TBL] [Abstract][Full Text] [Related]
11. AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965. Dite TA; Langendorf CG; Hoque A; Galic S; Rebello RJ; Ovens AJ; Lindqvist LM; Ngoei KRW; Ling NXY; Furic L; Kemp BE; Scott JW; Oakhill JS J Biol Chem; 2018 Jun; 293(23):8874-8885. PubMed ID: 29695504 [TBL] [Abstract][Full Text] [Related]
12. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors. Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors. Al-Warhi T; El Kerdawy AM; Aljaeed N; Ismael OE; Ayyad RR; Eldehna WM; Abdel-Aziz HA; Al-Ansary GH Molecules; 2020 Apr; 25(9):. PubMed ID: 32349307 [TBL] [Abstract][Full Text] [Related]
14. Involvement of AMP-activated protein kinase and p38 mitogen-activated protein kinase in 8-Cl-cAMP-induced growth inhibition. Han JH; Ahn YH; Choi KY; Hong SH J Cell Physiol; 2009 Jan; 218(1):104-12. PubMed ID: 18756496 [TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing. Wu Y; Sarkissyan M; Mcghee E; Lee S; Vadgama JV Breast Cancer Res Treat; 2015 Jun; 151(3):529-39. PubMed ID: 25975952 [TBL] [Abstract][Full Text] [Related]
16. Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity. Qin M; Tian Y; Han X; Cao Q; Zheng S; Liu C; Wu X; Liu L; Meng Y; Wang X; Zhang H; Hou Y Bioorg Med Chem; 2020 Jun; 28(11):115486. PubMed ID: 32305182 [TBL] [Abstract][Full Text] [Related]
17. Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab. Luo J; Hong Y; Lu Y; Qiu S; Chaganty BK; Zhang L; Wang X; Li Q; Fan Z Cancer Lett; 2017 Jan; 384():39-49. PubMed ID: 27693630 [TBL] [Abstract][Full Text] [Related]
18. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942 [TBL] [Abstract][Full Text] [Related]
19. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783 [TBL] [Abstract][Full Text] [Related]
20. Introducing a simple model system for binding studies of known and novel inhibitors of AMPK: a therapeutic target for prostate cancer. Kumar R; Maurya R; Saran S J Biomol Struct Dyn; 2019 Feb; 37(3):781-795. PubMed ID: 29447108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]